A Phase 2 interventional study of REGN4461 and Matching Placebo in Familial Partial Lipodystrophy and Metabolic Abnormalities, sponsored by Regeneron Pharmaceuticals. Terminated at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lipodystrophy, Familial Partial with a site in United States — 2 open to participants now, 2 under way, 2 of them phase 3. Lipodystrophy, Familial Partial · United States.
Among the 11 studies in Lipodystrophy, Familial Partial with a site in United States, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 4 in phase 2, and was the 8th registered.
20 studies on the registry are indexed under Lipodystrophy, Familial Partial; 5 are open to participants now.
Browse Lipodystrophy, Familial Partial studies →2 of the 11 studies in Lipodystrophy, Familial Partial with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Brazil, France
Ages 2+
Chiesi Farmaceutici S.p.A. · Sites in United States
Ages 13+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Lipodystrophy, Familial Partial studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4
First in 2014; this study’s year is marked. 1 started in 2022.
This study's enrollment of 20 is above the median of 16 across 14 interventional studies indexed under Lipodystrophy, Familial Partial.
Median enrollment 12 across the 10 interventional studies, 257 across the 1 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 8 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Lipodystrophy, Familial Partial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lipodystrophy, Familial Partial with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin \<8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL
The primary objectives will be evaluated for patients in Cohort A only:
The following secondary objectives of the study will be evaluated for Cohort B and for the combined set of Cohorts A plus B:
The following secondary objectives of the study will be evaluated for Cohorts A and B separately, and for the combined set of Cohorts A plus B:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized to placebo for 12 weeks and then crossover to REGN4461 for 12 weeks
Drug: REGN4461 · Drug: Matching Placebo
Randomized to receive REGN4461 for 24 weeks
Drug: REGN4461
Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Also known as: mibavademab
Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)
Percentage change in fasting serum TG was reported for participants with elevated baseline fasting TG (\> 200 mg/dL) and with baseline leptin \< 8.0 ng/mL (Cohort A).
Time frame: Baseline to week 12
Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)
Change in HbA1c was reported for participants with elevated baseline HbA1c (\> 7.0%) and with baseline leptin \< 8.0 ng/mL (Cohort A).
Time frame: Baseline to week 12
Percent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B)
Percent change in fasting serum TG was reported for participants with elevated baseline fasting TG (\>200 mg/dL) in Cohort B and Cohorts A + B.
Time frame: Baseline to week 12
Change From Baseline to Week 12 in HbA1c (Cohorts B and A + B)
Change in HbA1c was reported for participants with elevated baseline HbA1c (\>7.0%) in Cohort B and Cohorts A + B.
Time frame: Baseline to week 12
Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 1)
Percent change in fasting serum TG was reported for participants in Study Arm 1.
Time frame: Baseline, Week 12, Week 24
Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 2)
Percent change in fasting serum TG was reported for participants in Study Arm 2.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 1)
Change from baseline in HbA1c was reported for participants in Study Arm 1.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 2)
Change from baseline in HbA1c was reported for participants in Study Arm 2.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 1)
Change from baseline in fasting glucose was reported for participants in Study Arm 1.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 2)
Change from baseline in fasting glucose was reported for participants in Study Arm 2.
Time frame: Baseline, Week 12, Week 24
Percent Change From Baseline to Weeks 12 and 24 in Liver Fat Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) (Study Arm 1)
Percent change from baseline in MRI-PDFF was reported for participants with baseline MRI-PDFF ≥8.5% in Study Arm 1.
Time frame: Baseline, Week 12, Week 24
Percent Change From Baseline to Weeks 12 and 24 in Liver Fat MRI-PDFF (Study Arm 2)
Percent change from baseline in MRI-PDFF was reported for participants with baseline liver fat MRI-PDFF ≥8.5% in Study Arm 2.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Highest Hunger Score
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The highest hunger score asked participants to rate their highest hunger that day on a scale from 0 to 4, with higher scores representing the higher perceived hunger. A negative change from baseline indicated a reduction in perceived hunger.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Lowest Hunger Score
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The lowest hunger score asked participants to rate their lowest hunger that day on a scale from 0 to 4, with higher scores indicating higher perceived hunger. A negative change from baseline score indicated a reduction in perceived lowest hunger.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Felt Hungry Score
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among participants with lipodystrophy. The felt hungry score asked how much time participants felt hunger that day on a scale from 0 to 4, with higher scores indicating more time feeling hungry. A negative change from baseline score indicated a reduction in time spent feeling hungry.
Time frame: Baseline, Week 12, Week 24
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Fullness Score
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The fullness score asked participants to rate how often they felt full after eating that day on a scale from 0 to 4, with higher scores indicating higher feeling of fullness. A negative change from baseline indicated a reduced feeling of fullness.
Time frame: Baseline, Week 12, Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Day 169
Concentrations of REGN4461 in Serum
Time frame: Weeks 0, 1, 2, 3, 4, 5, 6, 9, 12, 13, 14, 15, 16, 17, 18, 21, 28, 32 and 36. Weeks 0 and 12 collected pre- and post-dose. All other time points were only pre-dose.
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response
Time frame: Up to Day 281
| Milestone | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 |
|---|---|---|---|---|
| Started | 6 | 6 | 4 | 4 |
| Completed treatment during dbtp | 5 | 6 | 4 | 4 |
| Completed treatment during sbtp | 5 | 5 | 3 | 4 |
| Completed | 6 | 6 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
Percentage change in fasting serum TG was reported for participants with elevated baseline fasting TG (\> 200 mg/dL) and with baseline leptin \< 8.0 ng/mL (Cohort A).
| percent change | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 |
|---|---|---|
| Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A) | -11.30 ± 46.306 | -38.97 ± 16.998 |
Change in HbA1c was reported for participants with elevated baseline HbA1c (\> 7.0%) and with baseline leptin \< 8.0 ng/mL (Cohort A).
| percentage of glycated hemoglobin | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 |
|---|---|---|
| Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A) | -0.05 ± 0.451 | -1.08 ± 1.108 |
Percent change in fasting serum TG was reported for participants with elevated baseline fasting TG (\>200 mg/dL) in Cohort B and Cohorts A + B.
| percent change | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B) | 36.78 ± 44.863 | -35.59 ± 8.754 | 10.07 ± 49.689 | -37.62 ± 13.752 |
Change in HbA1c was reported for participants with elevated baseline HbA1c (\>7.0%) in Cohort B and Cohorts A + B.
| percentage of glycated hemoglobin | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|
| Change From Baseline to Week 12 in HbA1c (Cohorts B and A + B) | -0.20 ± 0.283 | -0.90 ± 0.964 | -0.10 ± 0.379 | -1.01 ± 0.988 |
Percent change in fasting serum TG was reported for participants in Study Arm 1.
| percent change | Arm 1 Cohort A: Placebo to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 |
|---|---|---|---|
| Week 12 | -11.30 ± 46.306 | 36.78 ± 44.863 | 10.07 ± 49.689 |
| Week 24 | -29.79 ± 35.109 | -8.96 ± 13.673 | -23.84 ± 30.923 |
Percent change in fasting serum TG was reported for participants in Study Arm 2.
| percent change | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|
| Week 12 | -38.97 ± 16.998 | -35.59 ± 8.754 | -37.62 ± 13.752 |
| Week 24 | -30.77 ± 48.883 | -5.30 ± 51.158 | -18.04 ± 48.282 |
Change from baseline in HbA1c was reported for participants in Study Arm 1.
| percentage of glycated hemoglobin | Arm 1 Cohort A: Placebo to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 |
|---|---|---|---|
| Week 12 | -0.10 ± 0.406 | 0.13 ± 0.427 | 0.00 ± 0.406 |
| Week 24 | -0.78 ± 0.694 | 0.13 ± 0.802 | -0.44 ± 0.826 |
Change from baseline in HbA1c was reported for participants in Study Arm 2.
| percentage of glycated hemoglobin | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|
| Week 12 | -0.92 ± 1.068 | -0.78 ± 0.826 | -0.86 ± 0.931 |
| Week 24 | -0.98 ± 1.357 | -0.50 ± 1.068 | -0.77 ± 1.188 |
Change from baseline in fasting glucose was reported for participants in Study Arm 1.
| milligrams per deciliter (mg/dL) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 |
|---|---|---|---|
| Week 12 | 4.8 ± 29.55 | 0.0 ± 60.37 | 2.7 ± 42.54 |
| Week 24 | 7.2 ± 29.65 | -15.5 ± 6.36 | 0.7 ± 26.75 |
Change from baseline in fasting glucose was reported for participants in Study Arm 2.
| mg/dL | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|
| Week 12 | -5.2 ± 36.55 | -19.5 ± 22.87 | -10.9 ± 31.17 |
| Week 24 | 1.8 ± 26.35 | -12.3 ± 58.59 | -5.3 ± 42.71 |
Percent change from baseline in MRI-PDFF was reported for participants with baseline MRI-PDFF ≥8.5% in Study Arm 1.
| percent change | Arm 1 Cohort A: Placebo to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 |
|---|---|---|---|
| Week 12 | -11.44 ± 18.576 | -0.74 ± 9.919 | -7.16 ± 15.214 |
| Week 24 | -47.21 ± 22.176 | 44.81 ± NA | -16.54 ± 55.394 |
Percent change from baseline in MRI-PDFF was reported for participants with baseline liver fat MRI-PDFF ≥8.5% in Study Arm 2.
| percent change | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|
| Week 12 | -17.05 ± 25.788 | -18.80 ± 17.300 | -17.92 ± 20.351 |
| Week 24 | -24.33 ± 27.151 | -19.53 ± 19.324 | -22.27 ± 22.353 |
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The highest hunger score asked participants to rate their highest hunger that day on a scale from 0 to 4, with higher scores representing the higher perceived hunger. A negative change from baseline indicated a reduction in perceived hunger.
| score on a scale | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|
| Week 12 | -0.060 ± 0.9009 | -0.538 ± 0.4679 | -0.240 ± 0.2483 | -0.415 ± 0.7539 | -0.132 ± 0.6929 | -0.489 ± 0.5614 |
| Week 24 | -0.330 ± 0.3684 | -0.018 ± 0.6228 | -0.383 ± 0.1550 | -0.285 ± 0.6180 | -0.350 ± 0.2919 | -0.137 ± 0.5975 |
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The lowest hunger score asked participants to rate their lowest hunger that day on a scale from 0 to 4, with higher scores indicating higher perceived hunger. A negative change from baseline score indicated a reduction in perceived lowest hunger.
| score on a scale | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|
| Week 12 | 0.185 ± 0.8013 | -0.475 ± 0.4630 | -0.338 ± 0.4287 | -0.173 ± 0.3625 | -0.024 ± 0.7006 | -0.354 ± 0.4328 |
| Week 24 | -0.128 ± 0.0622 | 0.046 ± 0.6776 | -0.103 ± 0.2230 | 0.308 ± 0.9603 | -0.119 ± 0.1288 | 0.162 ± 0.7710 |
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among participants with lipodystrophy. The felt hungry score asked how much time participants felt hunger that day on a scale from 0 to 4, with higher scores indicating more time feeling hungry. A negative change from baseline score indicated a reduction in time spent feeling hungry.
| score on a scale | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|
| Week 12 | 0.248 ± 0.8642 | -0.550 ± 0.5334 | -0.168 ± 0.2900 | 0.008 ± 0.9139 | 0.082 ± 0.6993 | -0.327 ± 0.7206 |
| Week 24 | 0.016 ± 0.3932 | 0.120 ± 0.4374 | -0.183 ± 0.0603 | -0.138 ± 0.6595 | -0.059 ± 0.3163 | 0.006 ± 0.5265 |
The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The fullness score asked participants to rate how often they felt full after eating that day on a scale from 0 to 4, with higher scores indicating higher feeling of fullness. A negative change from baseline indicated a reduced feeling of fullness.
| score on a scale | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|
| Week 12 | 0.063 ± 1.1988 | -0.267 ± 0.5381 | -1.180 ± 0.3764 | -0.535 ± 0.5736 | -0.434 ± 1.1216 | -0.374 ± 0.5383 |
| Week 24 | -0.182 ± 0.6474 | 0.012 ± 0.6474 | -1.193 ± 0.6630 | -0.178 ± 0.8032 | -0.561 ± 0.7994 | -0.072 ± 0.6793 |
| Participants | DBTP Arm 1 Cohort A: Placebo | DBTP Arm 2 Cohort A: REGN4461 | DBTP Arm 1 Cohort B: Placebo | DBTP Arm 2 Cohort B: REGN4461 | DBTP Arm 1 Combined Cohort A + B: Placebo | DBTP Arm 2 Combined Cohort A + B: REGN4461 | SBTP Arm 1 Cohort A: Placebo to REGN4461 | SBTP Arm 2 Cohort A: REGN4461 to REGN4461 | SBTP Arm 1 Cohort B: Placebo to REGN4461 | SBTP Arm 2 Cohort B: REGN4461 to REGN4461 | SBTP Arm 1 Combined Cohort A + B: Placebo to REGN4461 | SBTP Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 4 | 5 | 4 | 4 | 8 | 9 | 3 | 5 | 3 | 4 | 6 | 9 |
| milligrams per liter (mg/L) | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|
| Week 0 (pre-dose) | 0 ± 0 | 0 ± 0 |
| Week 0 (post-dose) | 0 ± 0 | 232 ± 83.8 |
| Week 1 (pre-dose) | 0 ± 0 | 64.3 ± 24.9 |
| Week 2 (pre-dose) | 0 ± 0 | 52.5 ± 13.3 |
| Week 3 (pre-dose) | 0 ± 0 | 60.2 ± 19.0 |
| Week 4 (pre-dose) | 0 ± 0 | 58.8 ± 23.8 |
| Week 5 (pre-dose) | 0 ± 0 | 62.0 ± 36.1 |
| Week 6 (pre-dose) | 0 ± 0 | 68.8 ± 38.8 |
| Week 9 (pre-dose) | 0 ± 0 | 79.6 ± 49.2 |
| Week 12 (pre-dose) | 0 ± 0 | 87.1 ± 57.8 |
| Week 12 (post-dose) | 252 ± 50.7 | 87.6 ± 49.7 |
| Week 13 (pre-dose) | 62.4 ± 17.5 | 97.6 ± 68.6 |
| Week 14 (pre-dose) | 56.6 ± 17.6 | 92.8 ± 68.0 |
| Week 15 (pre-dose) | 64.2 ± 29.6 | 90.5 ± 59.1 |
| Week 16 (pre-dose) | 68.8 ± 24.3 | 103 ± 76.4 |
| Week 17 (pre-dose) | 73.4 ± 30.8 | 92.1 ± 73.3 |
| Week 18 (pre-dose) | 75.1 ± 27.1 | 95.0 ± 79.3 |
| Week 21 (pre-dose) | 89.3 ± 40.0 | 72.9 ± 51.4 |
| Week 28 (pre-dose) | 10.9 ± 12.0 | 16.0 ± 23.4 |
| Week 32 (pre-dose) | 0.0663 ± 0.0705 | 0.189 ± 0.281 |
| Week 36 (pre-dose) | 0.0110 ± 0.0330 | 0.0373 ± 0.0788 |
| Participants | Arm 1 Combined Cohort A + B: Placebo to REGN4461 | Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 |
|---|---|---|
| Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response | 0 | 0 |
Collected over From signing of informed consent up to day 281 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBTP Arm 1 Cohort A: Placebo | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| DBTP Arm 2 Cohort A: REGN4461 | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| DBTP Arm 1 Cohort B: Placebo | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| DBTP Arm 2 Cohort B: REGN4461 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| SBTP Arm 1 Cohort A: Placebo to REGN4461 | 0/5 (0%) | 1/5 (20%) | 3/5 (60%) |
| SBTP Arm 2 Cohort A: REGN4461 to REGN4461 | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| SBTP Arm 1 Cohort B: Placebo to REGN4461 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| SBTP Arm 2 Cohort B: REGN4461 to REGN4461 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | DBTP Arm 1 Cohort A: Placebo | DBTP Arm 2 Cohort A: REGN4461 | DBTP Arm 1 Cohort B: Placebo | DBTP Arm 2 Cohort B: REGN4461 | SBTP Arm 1 Cohort A: Placebo to REGN4461 | SBTP Arm 2 Cohort A: REGN4461 to REGN4461 | SBTP Arm 1 Cohort B: Placebo to REGN4461 | SBTP Arm 2 Cohort B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 1/6 | 0/6 | 1/4 | 0/4 | 0/5 | 0/6 | 0/3 | 0/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/6 | 0/6 | 0/4 | 0/4 | 1/5 | 0/6 | 0/3 | 0/4 |
| Angina pectorisCardiac disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/5 | 1/6 | 0/3 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 1/6 | 0/4 | 0/4 | 0/5 | 1/6 | 0/3 | 0/4 |
| HypertensionVascular disorders | 0/6 | 1/6 | 0/4 | 0/4 | 0/5 | 0/6 | 0/3 | 0/4 |
| Event | DBTP Arm 1 Cohort A: Placebo | DBTP Arm 2 Cohort A: REGN4461 | DBTP Arm 1 Cohort B: Placebo | DBTP Arm 2 Cohort B: REGN4461 | SBTP Arm 1 Cohort A: Placebo to REGN4461 | SBTP Arm 2 Cohort A: REGN4461 to REGN4461 | SBTP Arm 1 Cohort B: Placebo to REGN4461 | SBTP Arm 2 Cohort B: REGN4461 to REGN4461 |
|---|---|---|---|---|---|---|---|---|
| SinusitisInfections and infestations | 0/6 | 0/6 | 0/4 | 0/4 | 1/5 | 0/6 | 0/3 | 3/4 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/6 | 1/4 | 0/4 | 0/5 | 0/6 | 2/3 | 1/4 |
| COVID-19Infections and infestations | 1/6 | 2/6 | 1/4 | 2/4 | 0/5 | 1/6 | 1/3 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 3/6 | 1/4 | 2/4 | 1/5 | 1/6 | 0/3 | 1/4 |
| Abdominal painGastrointestinal disorders | 1/6 | 2/6 | 2/4 | 1/4 | 1/5 | 1/6 | 0/3 | 1/4 |
| DizzinessNervous system disorders | 0/6 | 3/6 | 0/4 | 0/4 | 0/5 | 0/6 | 1/3 | 0/4 |
| PainGeneral disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/5 | 0/6 | 0/3 | 2/4 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/4 | 2/4 | 0/5 | 2/6 | 0/3 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/6 | 1/4 | 0/4 | 2/5 | 2/6 | 1/3 | 0/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/6 | 1/6 | 0/4 | 0/4 | 2/5 | 0/6 | 0/3 | 0/4 |
The double-blind safety analysis set (DB SAF) included all randomized participants who received any study drug during the double-blind treatment period (DBTP).
| Age, Continuous(years) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| Mean | 40.5 ± 16.79 | 43.8 ± 13.47 | 48.0 ± 11.97 | 40.3 ± 12.82 | 43.0 ± 13.40 |
| Sex: Female, Male(Participants) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| Female | 5 | 6 | 3 | 4 | 18 |
| Male | 1 | 0 | 1 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 6 | 4 | 4 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 3 | 3 | 18 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Fasting Triglycerides Serum Concentration(milligrams per deciliter (mg/dL)) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| Geometric mean | 1100.9 (405 to 5681) | 737.8 (308 to 2487) | 675.0 (426 to 1534) | 336.2 (150 to 1376) | 698.3 (150 to 5681) |
| Hemoglobin A1c (HbA1c)(percentage of glycated hemoglobin) | Arm 1 Cohort A: Placebo to REGN4461 | Arm 2 Cohort A: REGN4461 to REGN4461 | Arm 1 Cohort B: Placebo to REGN4461 | Arm 2 Cohort B: REGN4461 to REGN4461 | Total |
|---|---|---|---|---|---|
| Mean | 8.8 ± 1.62 | 8.2 ± 1.76 | 6.9 ± 0.91 | 8.6 ± 2.06 | 8.2 ± 1.68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Feb 2022 to primary completion in Dec 2023, 21 months.
Results were first posted in Jul 2025, 1 year 6 months after primary completion. A results delay was requested in Nov 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mibavademab
Lipodystrophy, Familial Partial →